

## Supplementary Material

## **Supplementary Figure**

**Supplemental Figure 1.** Kaplan Meier survival analysis in COVID-19 patients with and without hypertension (overall, and stratified by non-severe and severe COVID-19 infection) in total 1833

patients, and in specific accompanied comorbidities.

	ients, and m spe	erne accompanieu comorbium			
Chronic			Chronic		
medical			medical		
histories of			histories of		
patients with	Median estimate	Survival Curve of patients	patients without	Median estimate	Suminal Cumus of notionts
hypertension	(95% CI)	Survival Curve of patients	hypertension	(95% CI)	Survival Curve of patients
Diabetes	18 (16.53, 19.16)		Diabetes	19 (17.67, 22.32)	
Cardiovascular	,	Patients with hypertension	Cardiovascular	18 (15.69, 19.30)	Patients without hypertension
diseases	15 (13.97, 16.06)	Log Ralin (p Value) <0.001	diseases	18 (13.09, 19.30)	1.0" Log Rank (p value)=0.857"Olatettes"Olatettes"Olatettes"Olatettes
Cerebrovascular	19 (16.17, 21.22)	0.8- Canol	Cerebrovascular	19 (16.69, 20.31)	0.8- Cancer Converting
diseases	19 (10.17, 21.22)		diseases	19 (10.09, 20.51)	er and a second s
Respiratory	18 (16.11, 19.88)		Respiratory	21 (18.37, 22.62)	
diseases	10 (10.11, 19.00)	A 0.4-	diseases	21 (10.57, 22.02)	54 0.4-
Cancer	14 (11.73, 16.26)	0.2- 4, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10	Cancer	18 (17.68, 20.11)	02-
Other	19 (17.61, 20.38)		Other	22 (18.71, 23.28)	The second secon
Overall	17 (16.43, 17.56)	0.0-	Overall	20 (19.10, 22.89)	0.0-
		0 10 20 30 40 50 60 Duration from onset to death		_ ( ( , , , , , , , , , , , , , , , , ,	o to 20 no do do do Duration from onset to death
Chronic			Chronic		
medical			medical		
histories of Non-severe			histories of		
patients with			Non-severe patients		
hypertension	Median estimate	Survival Curve of patients	without	Median estimate	Survival Curve of patients
nypertension	(95% CI)	Survivar Curve or patients	hypertension	(95% CI)	Survivar Curve or patients
Diabetes	21 (19.68, 22.31)		Diabetes	20 (14.01 ,20.98)	
Cardiovascular	16 (14.78, 17.21)	Non-severe patients with hypertension	Cardiovascular	20 (15.30, 19.69)	Non-severe patients without hypertension
diseases	10 (14.70, 17.21)	Log Rank (p value)=0.000	diseases	20 (13.30, 19.09)	Log Rank (p vatue)=0.740Babetes Cardovascular diseases
Cerebrovascular	22 (19.19, 24.80)	0.8-	Cerebrovascular	18 (12.93, 23.06)	0.8- Concer
diseases	22 (19.19, 21.00)		diseases	10 (12.93, 23.00)	
Respiratory	19 (16.55, 21.44)		Respiratory	20 (15.43, 21.56)	
diseases			diseases	(,,,,	2 0.4-
Cancer	15 (12.29, 17.70)	02- Little The Area	Cancer	19 (13.88, 18.11)	02-
Other	24 (21.75, 26.24)	Wind Decker and a second	Other	20 (15.58, 18.41)	
Overall	19 (18.06, 19.94)		Overall	20 (16.11, 22.38)	0.0" 0 10 20 30 40 60 60
		Duration from onset to death			Duration from onset to death
Chronic			Chronic		
medical			medical		
histories of			histories of		
Severe patients			Severe patients		
with	Median estimate	Survival Curve of patients	without	Median estimate	Survival Curve of patients
hypertension	(95% CI)	2	hypertension	(95% CI)	
Diabetes	16 (14.61, 17.38)	Severe patients with hyportension	Diabetes	17 (14.61, 19.38)	Severe patients without hypertension
Cardiovascular	11 (08.03, 13.97)	1.0" Log Rank (p value)=0.018Outputs	Cardiovascular	16 (13.03, 18.97)	10" Log Rank (p value)=0.621
diseases		Condervational diseases	diseases		OB OB OB
Cerebrovascular	16 (12.51, 19.48)	S Course	Cerebrovascular	14 (09.51, 18.48)	S L L L
diseases			diseases		
Respiratory	15 (12.45, 17.54)	Survey and the second s	Respiratory	17 (15.45, 18.54)	
diseases		S S	diseases		23
Cancer	11 (07.02, 14.97)	02-	Cancer	17 (15.02, 18.97)	0.2
Other	17 (15.54, 18.45)	00-	Other	16 (14.54, 17.45)	0.0-
Overall	15 (14.09, 15.90)	0 10 20 30 40 50 60 Duration from onset to death	Overall	17 (16.09, 17.90)	່ 10 20 30 40 50 60 Duration from onset to death
	· · · · · · · · · · · · · · · · · · ·			, , ,	



## **Supplemental Figure 1 legend**

The survival curves for patients comorbid with diabetes were in blue, the green curves were for those with cardiovascular disease, the grey ones were for cerebrovascular diseases, the purple were for the respiratory diseases, the yellow were for cancer, and the red were for patients with other comorbidities.

The difference in the survival time between the two groups of COVID-19 patients (with hypertension and without hypertension) was examined using the Log rank test. The p value was (0.015) for overall, (0.075) for non-sever, and (0.014) for severe COVID-19 patients. Those for the accompanying comorbidities among patients with versus without hypertension were (0.46) for diabetes, (0.045) for cardiovascular diseases, (0.86) for cerebrovascular diseases, (0.041) for respiratory diseases, (0.021) for cancer, and (0.048) for other diseases.